Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

5/28/24 8:03:03 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $BNGO alert in real time by email

Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024.

Get the next $BNGO alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BNGO

Date	Price Target	Rating	Analyst
11/15/2024		Buy → Neutral	Ladenburg Thalmann
9/10/2024		Buy → Neutral	BTIG Research
1/5/2023	$4.00	Sector Outperform	Scotiabank
12/12/2022	$3.50	Buy	BTIG Research
7/18/2022	$12.00	Outperform	Oppenheimer

More analyst ratings

$BNGO
Press Releases

Fastest customizable press release news feed in the world

View All

9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today's virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical structural variants and accelerating the precision and depth of genomic analysis of leukemias, lymphomas, and multiple myeloma. There are more than 1000 registered attendees from 70 countries across 6

2/24/26 8:00:00 AM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform for researchers to present cutting-edge findings and share insights into emerging applications of OGM technology. Join leading scientists from around the world as they highlight breakthroughs in OGM from February 23-26, 2026. The four-day event will feature presentations from over 30 researchers across North America, Europe, and Asia, covering research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic dis

2/9/26 9:05:00 AM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to detect genomic alterations introduced by different gene editing technologies, including transposons, lentiviral transduction, and CRISPR-Cas9-mediated locus insertion. The results suggest that OGM could be a valuable tool for quality control (QC) of cell-line genome integrity that identifies potentially deleterious alterations in pre-clinical and clinical development of gene editing therapies. OGM was selected as a genome-wide, unbiased method to det

2/4/26 8:00:00 AM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

$BNGO
Financials

Live finance-specific insights

View All

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at htt

10/30/25 4:05:00 PM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I'm very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives

8/14/25 4:01:00 PM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, August 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/tnombut6/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

7/31/25 4:05:00 PM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

$BNGO
Leadership Updates

Live Leadership Updates

View All

LeddarTech Appoints Chris Stewart as Chief Financial Officer

QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

11/15/23 12:07:00 AM ET

$BNGO

$PRSR

$TSLA

Biotechnology: Laboratory Analytical Instruments

Industrials

Blank Checks

Finance

Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

8/14/23 8:00:00 AM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

11/10/22 8:00:00 AM ET

$BNGO

Biotechnology: Laboratory Analytical Instruments

Industrials

Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BNGO

Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BNGO

$BNGO
SEC Filings

Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Bionano Genomics Inc.

Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BNGO
Analyst Ratings

Bionano Genomics downgraded by Ladenburg Thalmann

Bionano Genomics downgraded by BTIG Research

Scotiabank initiated coverage on Bionano Genomics with a new price target

$BNGO
Insider Trading

CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

$BNGO
Press Releases

9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies

Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

$BNGO
Financials

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

$BNGO
Leadership Updates

LeddarTech Appoints Chris Stewart as Chief Financial Officer

Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

$BNGO
Large Ownership Changes

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BNGO

Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BNGO

$BNGO SEC Filings

Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Bionano Genomics Inc.

Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BNGO Analyst Ratings

Bionano Genomics downgraded by Ladenburg Thalmann

Bionano Genomics downgraded by BTIG Research

Scotiabank initiated coverage on Bionano Genomics with a new price target

$BNGO Insider Trading

CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

$BNGO Press Releases

9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies

Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

$BNGO Financials

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

$BNGO Leadership Updates

LeddarTech Appoints Chris Stewart as Chief Financial Officer

Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

$BNGO Large Ownership Changes

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

Recent Analyst Ratings for
$BNGO

Recent Analyst Ratings for
$BNGO

$BNGO
SEC Filings

$BNGO
Analyst Ratings

$BNGO
Insider Trading

$BNGO
Press Releases

$BNGO
Financials

$BNGO
Leadership Updates

$BNGO
Large Ownership Changes